@article{fdi:010040704,
  title = {{D}ramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern {B}enin},
  author = {{A}ubouy, {A}gn{\`e}s and {F}ievet, {N}adine and {B}ertin, {G}wladys and {S}agbo, {J}ean {C}. and {K}ossou, {H}. and {K}inde {G}azard, {D}. and {K}iniffo, {R}. and {M}assougbodji, {A}. and {D}eloron, {P}hilippe},
  editor = {},
  language = {{ENG}},
  abstract = {{O}bjective {T}o evaluate the in vivo therapeutic efficacy of chloroquine ({CQ}), sulfadoxine-pyrimethamine ({SP}) and mefloquine ({MQ}) in children presenting with uncomplicated malaria in {B}enin. {M}ethods {D}rug efficacy was tested according to the {WHO} in vivo 28-day protocol. {F}or failures that occurred after 7 days of follow-up, paired pre- and post-treatment blood samples were genotyped at msp1 and msp2 loci to distinguish new infections and recrudescent strains. {C}hildren enrolled were randomly assigned to a therapeutic group ({CQ}, n = 14; {SP}, n = 42; {MQ}, n = 44). {T}he number of {CQ} treatment was intentionally restricted after 1 month, as its use was considered to constitute a danger for children. {R}esults {C}hloroquine and {SP} showed very high failure rates (85.7% and 50%, respectively), whereas {MQ} treatment was successful in 97.5%. {T}he molecular tool allowed to re-evaluate two new infections previously considered as failures. {C}onclusions {C}hloroquine should no longer be used to treat children presenting with {P}lasmodium falciparum malaria in {B}enin.},
  keywords = {falciparum malaria ; chloroquine ; sulfadoxine pyrimethamine ; mefloquine ; drug efficacy ; benin},
  booktitle = {},
  journal = {{T}ropical {M}edicine and {I}nternational {H}ealth},
  volume = {12},
  numero = {7},
  pages = {886--894},
  ISSN = {1360-2276},
  year = {2007},
  DOI = {10.1111/j.1365-3156.2007.01859.x},
  URL = {https://www.documentation.ird.fr/hor/fdi:010040704},
}